Navigation Links
Mylan Announces XELODA® Settlement and License Agreement
Date:9/21/2011

PITTSBURGH, Sept. 21, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement and license agreement with Hoffman La Roche Inc. resolving litigation related to XELODA® Tablets, 150 mg and 500 mg, USP, known generically as Capecitabine Tablets. This product is an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.

Pursuant to the agreement, the litigation was dismissed on Sept. 21, 2011.  Additional details are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. XELODA had U.S. sales of $570 million for the twelve months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the litigation settlement. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
2. Mylan Launches Generic Version of Uroxatral® Tablets
3. Mylan Announces U.S. PTO Intends to Reissue Two Perforomist® Patents to Dey Pharma
4. Mylan Launches First Generic Version of Entocort EC® Capsules
5. Mylan Receives Approval for Generic Version of Aricept® Tablets
6. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
7. Mylan Launches Generic Version of Roxicodone® Tablets
8. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
9. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
10. Mylan Launches First Generic Version of Amrix® Capsules
11. Mylan Launches Generic Version of Risperdal® M-Tab®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities ... ... ... ... ...
(Date:5/3/2016)... Ore. , May 3, 2016   ... medical technology, today announced Food and Drug Administration ... resynchronization defibrillator that provides heart failure patients with ... Iperia devices also have remote monitoring with daily ... adapts the heart rate in response to physiological ...
(Date:5/3/2016)...   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month ... patients who tell their personal story and encourage those at risk to get tested and ... C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... the Wharton Seminars for Business Journalists , led by the Wharton ... business and economic issues.  This one-day program at the Wharton School’s San ...
(Date:5/5/2016)... ... May 05, 2016 , ... An ... all U.S. states and certain Canadian provinces is now available from the International ... Institute (WCRI). , The report, Workers’ Compensation Laws as of January ...
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of ... hair loss treatment. Dr. Stong is double board certified and the only facial ... the treatment of hair loss. Non-surgical therapies such as stem cells can be used ...
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
Breaking Medicine News(10 mins):